Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2024 16:05 ET | Source: Relmada Therapeutics

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on track to initiate Phase 1 study...
August 05, 2024 07:30 ET | Source: Relmada Therapeutics

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system...
December 08, 2021 16:19 ET | Source: Relmada Therapeutics

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...